Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
McKinsey
Boehringer Ingelheim
Express Scripts
Merck

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR IMIPENEM AND CILASTATIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Imipenem And Cilastatin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00080496 ↗ Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2003-07-01 To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
NCT00081744 ↗ Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2002-11-01 Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
NCT00136201 ↗ Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-11-01 The primary objective of this study is to compare the safety and efficacy of an experimental antibiotic to a marketed antibiotic in the treatment of Chinese subjects with complicated intra-abdominal infections.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imipenem And Cilastatin

Condition Name

Condition Name for Imipenem And Cilastatin
Intervention Trials
Bacterial Infections 7
Urinary Tract Infections 3
Sepsis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Imipenem And Cilastatin
Intervention Trials
Infections 21
Infection 19
Communicable Diseases 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imipenem And Cilastatin

Trials by Country

Trials by Country for Imipenem And Cilastatin
Location Trials
United States 70
China 41
Japan 21
Ukraine 18
Russian Federation 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Imipenem And Cilastatin
Location Trials
California 6
Ohio 4
North Carolina 4
Florida 4
Texas 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imipenem And Cilastatin

Clinical Trial Phase

Clinical Trial Phase for Imipenem And Cilastatin
Clinical Trial Phase Trials
Phase 4 6
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Imipenem And Cilastatin
Clinical Trial Phase Trials
Completed 19
Recruiting 7
Unknown status 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imipenem And Cilastatin

Sponsor Name

Sponsor Name for Imipenem And Cilastatin
Sponsor Trials
Merck Sharp & Dohme Corp. 13
Sinovent Pty Ltd. 6
Pfizer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Imipenem And Cilastatin
Sponsor Trials
Industry 35
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Medtronic
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.